Aura Biosciences, Inc. (NASDAQ:AURA) Director David Michael Johnson Acquires 20,000 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) Director David Michael Johnson purchased 20,000 shares of the company’s stock in a transaction on Friday, May 16th. The shares were purchased at an average price of $4.90 per share, with a total value of $98,000.00. Following the completion of the purchase, the director now directly owns 166,167 shares of the company’s stock, valued at $814,218.30. The trade was a 13.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aura Biosciences Stock Performance

AURA stock opened at $5.93 on Wednesday. Aura Biosciences, Inc. has a 1 year low of $4.35 and a 1 year high of $12.38. The firm has a market cap of $298.10 million, a P/E ratio of -3.43 and a beta of 0.43. The stock has a 50-day simple moving average of $5.85 and a 200-day simple moving average of $7.48.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Thursday, May 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.08). On average, equities research analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Wall Street Analysts Forecast Growth

AURA has been the subject of several research analyst reports. JMP Securities set a $19.00 price target on Aura Biosciences in a research note on Wednesday, March 26th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Citigroup reiterated an “outperform” rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, HC Wainwright set a $25.00 target price on Aura Biosciences in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences presently has a consensus rating of “Buy” and an average target price of $22.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new position in Aura Biosciences in the fourth quarter valued at about $50,000. GAMMA Investing LLC boosted its holdings in Aura Biosciences by 5,766.9% in the first quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock valued at $57,000 after purchasing an additional 9,573 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Aura Biosciences in the fourth quarter valued at about $87,000. Ascent Group LLC purchased a new position in Aura Biosciences in the first quarter valued at about $124,000. Finally, ProShare Advisors LLC purchased a new position in Aura Biosciences in the fourth quarter valued at about $127,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.